Introgen says Advexin p53 therapy demonstrates clinical benefit in inherited cancer

By Elaine Rigoli

Tampa, Fla., June 2 - Introgen Therapeutics, Inc. presented data Friday describing the beneficial effects and key markers of clinical activity in a cancer patient with Li-Fraumeni Syndrome (LFS), a genetic disorder characterized by inherited mutations in the p53 tumor suppressor gene.

Introgen said the treatment of Li-Fraumeni tumors with Advexin, Introgen's p53 therapy, represents the epitome of targeted therapy as the cause of these cancers is due to abnormal p53 function that is directly addressed by Advexin treatment.

"In addition to providing targeted therapy for Li-Fraumeni cancer patients who need novel treatments, the results of our study defined important markers to guide Advexin therapy of other cancers with p53 abnormalities that are very common in most types of cancer," Neil Senzer, the lead clinical investigator of the study, said in a news release.

Treatment of a tumor in an LFS patient with Advexin led to improvement of tumor-related symptoms and resulted in a complete response as determined by positron emission tomography scans.

In addition, performance of molecular studies with biopsies of the tumor before and after treatment identified key markers of p53 pathway abnormalities that are used to predict and evaluate the effects of Advexin therapy, the release said.

Introgen is an Austin, Texas-based biopharmaceutical company developing targeted molecular therapies for the treatment of cancer and other diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.